The whistleblower claims brought by a former sales representative for Abbott Laboratories alleging that the company illegally marketed its drug TriCor for off-label uses have survived a motion to dismiss in federal court.
February 03, 2014 at 12:00 AM
1 minute read
The whistleblower claims brought by a former sales representative for Abbott Laboratories alleging that the company illegally marketed its drug TriCor for off-label uses have survived a motion to dismiss in federal court.
The case falls in line with the Third Circuit’s shift toward a more relaxed pleading standard for off-label marketing claims under Federal Rule of Civil Procedure 9(b).
Presented by BigVoodoo
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
